The Inflation Reduction Act (IRA) is setting new benchmarks for pharmaceutical pricing through Medicare’s maximum fair prices (MFPs). Our latest RPR™-powered research provides an in-depth analysis of how these changes are reshaping the market and what they mean for your business.
In this comprehensive report, we explore:
- How payers are leveraging MFPs to negotiate more favorable prices and implement cost-saving strategies.
- The downstream effects on private health plans, including increased utilization management and rebate demands.
- What manufacturers need to do to maintain competitive positioning, from strengthening clinical differentiation to refining rebate strategies.
Whether you’re navigating new price expectations or preparing for evolving payer dynamics, our findings offer actionable insights to guide your strategy.
Download the full report now
NOTE: The survey was carried out using our RPR stakeholder engagement solution. Book a meeting to allow us to explain how RPR can support your project: solutions@genesisrg.com.
